Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes

DOI PDF 被引用文献2件
  • James M. Lawrence
    Diabetes and Lipid Research Group, Wolfson Centre, Royal United Hospital, Bath, U.K.
  • Julia Reid
    Diabetes and Lipid Research Group, Wolfson Centre, Royal United Hospital, Bath, U.K.
  • Gordon J. Taylor
    Senior Statistician, Department of Medical Sciences, University of Bath, Bath, U.K.
  • Chris Stirling
    Diabetes and Lipid Research Group, Wolfson Centre, Royal United Hospital, Bath, U.K.
  • John P.D. Reckless
    Diabetes and Lipid Research Group, Wolfson Centre, Royal United Hospital, Bath, U.K.

抄録

<jats:p>OBJECTIVE—To compare effects of different oral hypoglycemic drugs as first-line therapy on lipoprotein subfractions in type 2 diabetes.</jats:p> <jats:p>RESEARCH DESIGN AND METHODS—Sixty overweight type 2 diabetic patients not on lipid-lowering therapy were randomized to metformin, pioglitazone, or gliclazide after a 3-month dietary run-in. Drug doses were uptitrated for 3 months to optimize glycemia and were kept fixed for a further 3 months. LDL subfractions (LDL1, LDL2, and LDL3) were prepared by density gradient ultracentrifugation at randomization and study end. Triglycerides, cholesterol, total protein, and phospholipids were measured and mass of subfractions calculated. HDL subfractions were prepared by precipitation. The primary end point was change in proportion of LDL as LDL3.</jats:p> <jats:p>RESULTS—HbA1c, triglycerides, glucose, and cholesterol were comparable across groups at baseline and over time. LDL3 mass and the LDL3-to-LDL ratio fell with pioglitazone (LDL3 mass 36.2 to 28.0 mg/dl, P &lt; 0.01; LDL3-to-LDL 19.2:13.3%, P &lt; 0.01) and metformin (42.7 to 31.5 mg/dl, P &lt; 0.01; 21.3:16.2%, P &lt; 0.01, respectively) with no change on gliclazide. LDL3 reductions were associated with reciprocal LDL1 increases. Changes were independent of BMI, glycemic control, and triglycerides. Total HDL cholesterol increased on pioglitazone (1.28 to 1.36 mmol/l, P = 0.02) but not gliclazide (1.39 to 1.37 mmol/l, P = NS) or metformin (1.26 to 1.18 mmol/l, P = NS), largely due to an HDL2 increase (0.3 to 0.4 mmol/l, P &lt; 0.05). HDL3 cholesterol fell on metformin (0.9 to 0.85 mmol/l, P &lt; 0.01). On pioglitazone and metformin, the HDL2-to-HDL3 ratio increased compared with no change on gliclazide.</jats:p> <jats:p>CONCLUSIONS—For the same improvement in glycemic control, pioglitazone and metformin produce favorable changes in HDL and LDL subfractions compared with gliclazide in overweight type 2 diabetic patients. Such changes may be associated with reduced atherosclerosis risk and may inform the choice of initial oral hypoglycemic agent.</jats:p>

収録刊行物

  • Diabetes Care

    Diabetes Care 27 (1), 41-46, 2004-01-01

    American Diabetes Association

被引用文献 (2)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ